Skip to content
Menu

Intellia Therapeutics, Inc. NTLA

Full chart Compare
Set alert

Price alert · NTLA

All alert types
10.27 USD +0.75 (+7.88%)

As ofNov 20, 2026, 1:25 PM EST

10.05 Day range 10.40
7.95 52-week range 18.48
YTD
+14.24%
1 year
+27.74%

5D -0.29 (-2.79%)

9.501010.50MonTueWedThuFri10.10
Market cap
1.44B
Revenue (ttm)
52.89M
EPS (ttm)
-3.26
Shares out
140.36M
Forward P/E
-3.53
YTD return
+14.24%
1-year return
+27.74%
50-day average
11.75
200-day average
12.91
Enterprise value
1.13B
Volume
4.65M
Avg volume
4.85M
Open
10.18
Previous close
9.52
Day's range
10.05 – 10.40
52-week range
7.95 – 18.48
Beta
1.82
Analysts
Buy
Price target
22.78 (+121.8%)
Earnings date
Feb 25, 2027

Key statistics

Price / sales
25.27
Price / book
2.18
Revenue growth
-48.00%
Free cash flow
-167.19M
Total cash
474.11M
Total debt
230.14M
Return on equity
-62.60%
Short % of float
39.80%

Fundamental scorecard

6 of 25 checks passed on NTLA’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
NTLA Revenue — quarterly 7.16M
NTLA Net income — quarterly -127.48M
NTLA EPS — quarterly -0.91

Earnings

NTLA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.75———
Nov 5, 2026Sep 30, 2026-0.79699-0.91-0.11-14.18%
Aug 6, 2026Jun 30, 2026-0.79927-0.800.00-0.09%
May 11, 2026Mar 31, 2026-0.92-0.81+0.11+11.96%
Feb 26, 2026Dec 31, 2025-0.99-0.83+0.16+16.16%
Nov 6, 2025Sep 30, 2025-1.02-0.92+0.10+9.80%

Upgrades / downgrades

NTLA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 6, 2026Barclaysinit—Underweight
Sep 9, 2026CitizensreitMarket OutperformMarket Outperform
Sep 9, 2026WedbushmainNeutralNeutral
Sep 9, 2026HC Wainwright & Co.reitBuyBuy
Aug 25, 2026CitizensreitMarket OutperformMarket Outperform
Aug 7, 2026Evercore ISI GroupupIn-LineOutperform

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on NTLA — it syncs with the Stock Master app.

Insider holders

NTLA insider holders
InsiderRelationLatest transactionDateShares held
BASTA JAMES EDMUNDGeneral CounselSaleMar 1, 2026156,794
CHASE WILLIAM JDirectorStock Award(Grant)Jun 8, 2026143,893
CLARK ELIANAChief Technology OfficerSaleMar 1, 202693,864
COHEN FREDERICK E. M.D. PH.D.DirectorStock Award(Grant)Jun 8, 2026216,653
DULAC EDWARD J IIIChief Financial OfficerSaleJul 21, 2026148,175
LEBWOHL DAVIDOfficerStock Award(Grant)Feb 26, 2026131,192

Institution ownership

NTLA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.11.42%16,035,423152.66MSep 29, 2026
ARK Investment Management, LLC11.35%15,925,221151.61MSep 29, 2026
State Street Corporation5.56%7,809,06074.34MSep 29, 2026
Vanguard Portfolio Management LLC5.26%7,389,66970.35MSep 29, 2026
Shaw D.E. & Co., Inc.4.32%6,064,71757.74MSep 29, 2026
Vanguard Capital Management LLC4.30%6,041,59957.52MSep 29, 2026

Fund ownership

NTLA fund ownership
Holder% heldSharesValueReported
ARK ETF Trust-ARK Innovation ETF7.88%11,062,565105.32MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.05%4,286,20040.80MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF3.05%4,286,32340.81MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.54%3,564,71433.94MSep 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.40%3,371,85132.10MOct 30, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.21%3,106,24229.57MJun 29, 2026